A contrary hypothesis is that efficacy of anti-PD1/L1 and anti-LAG3 may, in fact, be due to their anti-cancer rather than immune modulatory effects, in which case anti-PD1/L1 plus another anti-cancer therapy would be preferable over anti-PD1/L1 plus another immune activating/modulatory therapy. The gene discussed is LAG3; the disease is cancer.